Roger Thompson


Roger outside Chacaltaya laboratory, Bolivia; 2001
Roger Thompson is a co-founder and treasurer of Apex and was the leader of the Apex 2 expedition and deputy leader of the first Apex expedition. He is now an MRC Clinical Research Fellow and Specialist Registrar in Respiratory Medicine at the University of Sheffield.

Recent publications:

1. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial.

Bates MG, Thompson AA, Baillie JK, Sutherland AI, Irving JB, Hirani N, Webb DJ. High Alt Med Biol. 2011 Fall;12(3):207-14.PMID: 21962063

2. Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice.

Walmsley SR, Chilvers ER, Thompson AA, Vaughan K, Marriott HM, Parker LC, Shaw G, Parmar S, Schneider M, Sabroe I, Dockrell DH, Milo M, Taylor CT, Johnson RS, Pugh CW, Ratcliffe PJ, Maxwell PH, Carmeliet P, Whyte MK. J Clin Invest. 2011 Mar 1;121(3):1053-63. doi: 10.1172/JCI43273. Epub 2011 Feb 7.PMID: 21317538

3. Hypoxia selectively inhibits respiratory burst activity and killing of Staphylococcus aureus in human neutrophils.

McGovern NN, Cowburn AS, Porter L, Walmsley SR, Summers C, Thompson AA, Anwar S, Willcocks LC, Whyte MK, Condliffe AM, Chilvers ER. J Immunol. 2011 Jan 1;186(1):453-63. Epub 2010 Dec 6.PMID: 21135168

4. Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro.

Jackson SJ, Varley J, Sellers C, Josephs K, Codrington L, Duke G, Njelekela MA, Drummond G, Sutherland AI, Thompson AA, Baillie JK. High Alt Med Biol. 2010 Fall;11(3):217-22.PMID: 20919888

5. The citric acid cough threshold and the ventilatory response to carbon dioxide on ascent to high altitude.

Thompson AA, Baillie JK, Bates MG, Schnopp MF, Simpson A, Partridge RW, Drummond GB, Mason NP. Respir Med. 2009 Aug;103(8):1182-8. Epub 2009 Mar 19.PMID: 19303278

6. Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial.

Baillie JK, Thompson AA, Irving JB, Bates MG, Sutherland AI, Macnee W, Maxwell SR, Webb DJ. QJM. 2009 May;102(5):341-8. Epub 2009 Mar 9.PMID: 19273551

7. NT-proBNP does not rise on acute ascent to high altitude.

Toshner MR, Thompson AA, Irving JB, Baillie JK, Morton JJ, Peacock AJ. High Alt Med Biol. 2008 Winter;9(4):307-10.PMID: 19115915

8. Manual assessment of the initial fall in blood pressure after orthostatic challenge at high altitude.

Mytton OT, Simpson A, Thompson AA, Oram RA, Darowski A, Yu LM, Collier DJ, Pollard AJ. Wilderness Environ Med. 2008 Winter;19(4):225-32. PMID: 19099326

9. Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude.

Baillie JK, Bates MG, Thompson AA, Waring WS, Partridge RW, Schnopp MF, Simpson A, Gulliver-Sloan F, Maxwell SR, Webb DJ. Chest. 2007 May;131(5):1473-8.PMID: 17494796

10. Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema.

Bates MG, Thompson AA, Baillie JK. Curr Opin Investig Drugs. 2007 Mar;8(3):226-31. PMID: 17408118

11. Endothelial nitric oxide synthase polymorphisms do not influence pulmonary artery systolic pressure at altitude.

Smith EM, Baillie JK, Thompson AA, Irving JB, Porteous D, Webb DJ. High Alt Med Biol. 2006 Fall;7(3):221-7.PMID: 16978134

12. Change in plasma vascular endothelial growth factor during onset and recovery from acute mountain sickness.

Dorward DA, Thompson AA, Baillie JK, MacDougall M, Hirani N. Respir Med. 2007 Mar;101(3):587-94. Epub 2006 Aug 4.PMID: 16890420

13. Pericardial effusions in healthy lowlanders after acute ascent to high altitude.

Thompson AA, Baillie JK, Toshner M, Maxwell SR, Webb DJ, Irving JB. Heart. 2006 Apr;92(4):539-40.PMID: 16537774